{"id":536378,"date":"2026-06-18T09:30:53","date_gmt":"2026-06-18T09:30:53","guid":{"rendered":"https:\/\/www.newjerseyheadlines.com\/news\/story\/536378\/diabetic-peripheral-neuropathy-pipeline-2026-therapies-moa-insights-and-key-clinical-trial-updates-by-delveinsight-helixmith-lexicon-pharma-glenmark-pharma-praetego-mitsubishi-tanabe-pharma.html"},"modified":"2026-06-18T09:30:53","modified_gmt":"2026-06-18T09:30:53","slug":"diabetic-peripheral-neuropathy-pipeline-2026-therapies-moa-insights-and-key-clinical-trial-updates-by-delveinsight-helixmith-lexicon-pharma-glenmark-pharma-praetego-mitsubishi-tanabe-pharma","status":"publish","type":"post","link":"http:\/\/www.northcarolinaheadlines.com\/news\/story\/536378\/diabetic-peripheral-neuropathy-pipeline-2026-therapies-moa-insights-and-key-clinical-trial-updates-by-delveinsight-helixmith-lexicon-pharma-glenmark-pharma-praetego-mitsubishi-tanabe-pharma.html","title":{"rendered":"Diabetic Peripheral Neuropathy Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Helixmith, Lexicon Pharma, Glenmark Pharma, Praetego, Mitsubishi Tanabe Pharma"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.abnewswire.com\/upload\/2026\/06\/1781724991.jpg\" style=\"border:none !important\" target=\"_blank\"><img decoding=\"async\" loading=\"lazy\" class=\"alignnone size-medium wp-image-29\" title=\"Diabetic Peripheral Neuropathy Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Helixmith, Lexicon Pharma, Glenmark Pharma, Praetego, Mitsubishi Tanabe Pharma\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/06\/1781724991.jpg\" alt=\"Diabetic Peripheral Neuropathy Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Helixmith, Lexicon Pharma, Glenmark Pharma, Praetego, Mitsubishi Tanabe Pharma\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic;padding:8px 0px\">As per DelveInsight\u2019s assessment, globally, Diabetic Peripheral Neuropathy pipeline constitutes 15+ key companies continuously working towards developing 20+ Diabetic Peripheral Neuropathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.<\/div>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\">The Diabetic Peripheral Neuropathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>&ldquo;Diabetic Peripheral Neuropathy Pipeline Insight, 2026&#8243;<\/strong> report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Peripheral Neuropathy Market.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Get a Free Sample PDF Report to know more about Diabetic Peripheral Neuropathy Pipeline Therapeutic Assessment-<\/strong><\/p>\n<p style=\"text-align: justify\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-peripheral-neuropathy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/diabetic-peripheral-neuropathy-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Some of the key takeaways from the Diabetic Peripheral Neuropathy Pipeline Report: <\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p class=\"caps\">Companies across the globe are diligently working toward developing novel Diabetic Peripheral Neuropathy treatment therapies with a considerable amount of success over the years.<\/p>\n<\/li>\n<li>\n<p>Diabetic Peripheral Neuropathy companies working in the treatment market are <strong>Praetego, Mitsubishi Tanabe Pharma, Regenacy Pharmaceuticals, WinSanTor, Helixmith, Lexicon Pharmaceuticals, Glenmark Pharmaceuticals, Regenacy Pharmaceuticals, Pure Green, Vertex Pharmaceuticals Incorporated, Eli Lilly and Company, and others<\/strong>, are developing therapies for the Diabetic Peripheral Neuropathy treatment<\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify\">\n<li>\n<p>Emerging Diabetic Peripheral Neuropathy therapies in the different phases of clinical trials are- <strong>PTG-630, MT-8554, Ricolinostat, WST 057, Engensis, VM202, LX9211, GRC 17536, Ricolinostat, CBD, VX-548, LY3857210, and others<\/strong> are expected to have a significant impact on the Diabetic Peripheral Neuropathy market in the coming years.<\/p>\n<\/li>\n<li>\n<p><strong>In April 2026, Vertex Pharmaceuticals<\/strong> advanced its ongoing Phase II clinical trial of VX-993, investigating its potential for managing pain associated with diabetic peripheral neuropathy (DPN). The study is assessing the oral investigational therapy&rsquo;s efficacy, safety, and tolerability in adults experiencing painful DPN.<\/p>\n<\/li>\n<li>\n<p><strong>In February 2026, Vertex Pharmaceuticals<\/strong> progressed recruitment and clinical development efforts for its Phase III program evaluating suzetrigine (VX-548) in patients with painful diabetic peripheral neuropathy. Suzetrigine, a first-in-class NaV1.8 pain-signal inhibitor, is being developed as a potential non-opioid therapy designed to offer effective pain relief while addressing the need for safer treatment alternatives.<\/p>\n<\/li>\n<li>\n<p><strong>In January 2026, Lexicon Pharmaceuticals<\/strong> reported a successful End-of-Phase II meeting with the U.S. FDA for pilavapadin, its investigational non-opioid treatment for Diabetic Peripheral Neuropathic Pain (DPNP). The agency expressed no concerns regarding the advancement of the candidate into Phase III registrational trials, clearing the path for the therapy&rsquo;s late-stage clinical development.<\/p>\n<\/li>\n<li>\n<p><strong>In August 2025, Following the FDA&rsquo;s milestone approval<\/strong> of the opioid-free acute pain therapy Journavx in January, Vertex Pharmaceuticals has encountered challenges in its efforts to broaden the drug&rsquo;s potential blockbuster use into various chronic pain indications. The company is aiming to secure an expansive label for Journavx (suzetrigine) in peripheral neuropathy (PNP), a chronic condition characterized by damage to nerves outside the brain and spinal cord. To support this strategy, Vertex has been conducting clinical studies evaluating Journavx across two specific PNP subtypes lumbosacral radiculopathy (LSR) and diabetic peripheral neuropathy (DPN) with the objective of obtaining approval for a broad PNP indication in a single step.<\/p>\n<\/li>\n<li>\n<p><strong>In May 2025, Novaremed AG,<\/strong> a privately owned clinical-stage biopharmaceutical company, has announced the completion of patient enrollment in its Phase 2b EN21-01 clinical trial (ClinicalTrials.gov ID: NCT05480228), which is sponsored by the National Institutes of Health (NIH). This study is focused on assessing NRD.E1, Novaremed&rsquo;s investigational non-opioid treatment for chronic pain linked to diabetic peripheral neuropathy. The trial is being funded through the NIH Helping to End Addiction Long-term (HEAL) Initiative.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Diabetic Peripheral Neuropathy Overview<\/strong><\/p>\n<p style=\"text-align: justify\">Diabetic Peripheral Neuropathy is a common complication of diabetes that affects the nerves in the hands, feet, and legs. It occurs due to prolonged high blood sugar levels that damage the peripheral nerves, leading to numbness, tingling, burning sensations, pain, or weakness, especially in the feet and legs. DPN can increase the risk of foot ulcers and infections, which may lead to serious complications if untreated. While there is no cure, managing blood sugar levels, along with medications for nerve pain, can help control symptoms and slow progression.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Explore the latest Diabetic Peripheral Neuropathy pipeline insights 2025, including emerging therapies, clinical trials, and market opportunities. Stay ahead in <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetic-peripheral-neuropathy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Diabetic Peripheral Neuropathy Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Emerging Diabetic Peripheral Neuropathy Drugs Under Different Phases of Clinical Development Include:<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p><strong>PTG-630:<\/strong> Praetego<\/p>\n<\/li>\n<li>\n<p><strong>MT-8554:<\/strong> Mitsubishi Tanabe Pharma<\/p>\n<\/li>\n<li>\n<p><strong>Ricolinostat:<\/strong> Regenacy Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p><strong>WST 057:<\/strong> WinSanTor<\/p>\n<\/li>\n<li>\n<p><strong>Engensis:<\/strong> Helixmith<\/p>\n<\/li>\n<li>\n<p><strong>VM202:<\/strong> Helixmith<\/p>\n<\/li>\n<li>\n<p><strong>LX9211:<\/strong> Lexicon Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p><strong>GRC 17536:<\/strong> Glenmark Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p><strong>Ricolinostat:<\/strong> Regenacy Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p><strong>CBD:<\/strong> Pure Green<\/p>\n<\/li>\n<li>\n<p><strong>VX-548:<\/strong> Vertex Pharmaceuticals Incorporated<\/p>\n<\/li>\n<li>\n<p><strong>LY3857210:<\/strong> Eli Lilly and Company<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Diabetic Peripheral Neuropathy Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify\">Diabetic Peripheral Neuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Infusion<\/p>\n<\/li>\n<li>\n<p>Intradermal<\/p>\n<\/li>\n<li>\n<p>Intramuscular<\/p>\n<\/li>\n<li>\n<p>Intranasal<\/p>\n<\/li>\n<li>\n<p>Oral<\/p>\n<\/li>\n<li>\n<p>Parenteral<\/p>\n<\/li>\n<li>\n<p>Subcutaneous<\/p>\n<\/li>\n<li>\n<p>Topical.<\/p>\n<\/li>\n<li>\n<p>Molecule Type<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Diabetic Peripheral Neuropathy Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify\">Diabetic Peripheral Neuropathy Products have been categorized under various Molecule types, such as<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Gene therapies<\/p>\n<\/li>\n<li>\n<p>Small molecule<\/p>\n<\/li>\n<li>\n<p>Product Type<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Diabetic Peripheral Neuropathy Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Diabetic Peripheral Neuropathy Assessment by Product Type<\/p>\n<\/li>\n<li>\n<p>Diabetic Peripheral Neuropathy By Stage and Product Type<\/p>\n<\/li>\n<li>\n<p>Diabetic Peripheral Neuropathy Assessment by Route of Administration<\/p>\n<\/li>\n<li>\n<p>Diabetic Peripheral Neuropathy By Stage and Route of Administration<\/p>\n<\/li>\n<li>\n<p>Diabetic Peripheral Neuropathy Assessment by Molecule Type<\/p>\n<\/li>\n<li>\n<p>Diabetic Peripheral Neuropathy by Stage and Molecule Type<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>DelveInsight&#8217;s Diabetic Peripheral Neuropathy Report covers around 20+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Late-stage products (Phase III)<\/p>\n<\/li>\n<li>\n<p>Mid-stage products (Phase II)<\/p>\n<\/li>\n<li>\n<p>Early-stage product (Phase I)<\/p>\n<\/li>\n<li>\n<p>Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li>\n<p>Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<li>\n<p>Route of Administration<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Further Diabetic Peripheral Neuropathy product details are provided in the report. Download the Diabetic Peripheral Neuropathy pipeline report to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetic-peripheral-neuropathy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">emerging Diabetic Peripheral Neuropathy therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Some of the key companies in the Diabetic Peripheral Neuropathy Therapeutics Market include:<\/strong><\/p>\n<p style=\"text-align: justify\">Key companies developing therapies for Diabetic Peripheral Neuropathy are &#8211; <em><strong>Eli Lilly and Company, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Aptinyx, Lexicon Pharmaceuticals, Lateral Pharma Pty Ltd., SIMR (Australia) Biotech Pty Ltd., WinSanTor, Inc., Helixmith, Lexicon Pharmaceuticals, Glenmark Pharmaceuticals, Regenacy Pharmaceuticals, Pure Green, Vertex Pharmaceuticals Incorporated, Daiichi Sankyo, Inc., Avazzia, Inc., and others.<\/strong><\/em><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Diabetic Peripheral Neuropathy Pipeline Analysis:<\/strong><\/p>\n<p style=\"text-align: justify\">The Diabetic Peripheral Neuropathy pipeline report provides insights into<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Peripheral Neuropathy with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li>\n<p>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Peripheral Neuropathy Treatment.<\/p>\n<\/li>\n<li>\n<p>Diabetic Peripheral Neuropathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>Diabetic Peripheral Neuropathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/p>\n<\/li>\n<li>\n<p>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Peripheral Neuropathy market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Download Sample PDF Report to know more about <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetic-peripheral-neuropathy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Diabetic Peripheral Neuropathy drugs and therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Diabetic Peripheral Neuropathy Pipeline Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Increasing prevalence of diabetes cases and growing aging population, rising R&amp;D activities for drug discovery and development are some of the important factors that are fueling the Diabetic Peripheral Neuropathy Market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Diabetic Peripheral Neuropathy Pipeline Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>However, high failure rate in clinical trials, stringent regulatory requirements, and longer approval time for drugs and other factors are creating obstacles in the Diabetic Peripheral Neuropathy Market growth.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Scope of Diabetic Peripheral Neuropathy Pipeline Drug Insight <\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p><strong>Coverage: Global<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Key Diabetic Peripheral Neuropathy Companies:<\/strong> Praetego, Mitsubishi Tanabe Pharma, Regenacy Pharmaceuticals, WinSanTor, Helixmith, Lexicon Pharmaceuticals, Glenmark Pharmaceuticals, Regenacy Pharmaceuticals, Pure Green, Vertex Pharmaceuticals Incorporated, Eli Lilly and Company, and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Diabetic Peripheral Neuropathy Therapies:<\/strong> PTG-630, MT-8554, Ricolinostat, WST 057, Engensis, VM202, LX9211, GRC 17536, Ricolinostat, CBD, VX-548, LY3857210, and others<\/p>\n<\/li>\n<li>\n<p><strong>Diabetic Peripheral Neuropathy Therapeutic Assessment:<\/strong> Diabetic Peripheral Neuropathy current marketed and Diabetic Peripheral Neuropathy emerging therapies<\/p>\n<\/li>\n<li>\n<p><strong>Diabetic Peripheral Neuropathy Market Dynamics: Diabetic Peripheral Neuropathy market drivers and Diabetic Peripheral Neuropathy market barriers <\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Request for Sample PDF Report for <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetic-peripheral-neuropathy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Diabetic Peripheral Neuropathy Pipeline Assessment and clinical trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify\">1. Diabetic Peripheral Neuropathy Report Introduction<\/p>\n<p style=\"text-align: justify\">2. Diabetic Peripheral Neuropathy Executive Summary<\/p>\n<p style=\"text-align: justify\">3. Diabetic Peripheral Neuropathy Overview<\/p>\n<p style=\"text-align: justify\">4. Diabetic Peripheral Neuropathy- Analytical Perspective In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify\">5. Diabetic Peripheral Neuropathy Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify\">6. Diabetic Peripheral Neuropathy Late Stage Products (Phase II\/III)<\/p>\n<p style=\"text-align: justify\">7. Diabetic Peripheral Neuropathy Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify\">8. Diabetic Peripheral Neuropathy Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify\">9. Diabetic Peripheral Neuropathy Preclinical Stage Products<\/p>\n<p style=\"text-align: justify\">10. Diabetic Peripheral Neuropathy Therapeutics Assessment<\/p>\n<p style=\"text-align: justify\">11. Diabetic Peripheral Neuropathy Inactive Products<\/p>\n<p style=\"text-align: justify\">12. Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<p style=\"text-align: justify\">13. Diabetic Peripheral Neuropathy Key Companies<\/p>\n<p style=\"text-align: justify\">14. Diabetic Peripheral Neuropathy Key Products<\/p>\n<p style=\"text-align: justify\">15. Diabetic Peripheral Neuropathy Unmet Needs<\/p>\n<p style=\"text-align: justify\">16 . Diabetic Peripheral Neuropathy Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify\">17. Diabetic Peripheral Neuropathy Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify\">18. Diabetic Peripheral Neuropathy Analyst Views<\/p>\n<p style=\"text-align: justify\">19. Appendix<\/p>\n<p style=\"text-align: justify\">20. About DelveInsight<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>About DelveInsight <\/strong><\/p>\n<p style=\"text-align: justify\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=diabetic-peripheral-neuropathy-pipeline-2026-therapies-moa-insights-and-key-clinical-trial-updates-by-delveinsight-helixmith-lexicon-pharma-glenmark-pharma-praetego-mitsubishi-tanabe-pharma\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679 <br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=diabetic-peripheral-neuropathy-pipeline-2026-therapies-moa-insights-and-key-clinical-trial-updates-by-delveinsight-helixmith-lexicon-pharma-glenmark-pharma-praetego-mitsubishi-tanabe-pharma\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>As per DelveInsight\u2019s assessment, globally, Diabetic Peripheral Neuropathy pipeline constitutes 15+ key companies continuously working towards developing 20+ Diabetic Peripheral Neuropathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts\/536378"}],"collection":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/comments?post=536378"}],"version-history":[{"count":0,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts\/536378\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/media?parent=536378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/categories?post=536378"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/tags?post=536378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}